Skip to Main Content

Author Details

Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
2011
29
15
PMIDPaper TitleJournal TitlePublished Year
36264026Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukaemia.Br J Haematol2023
37698624Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood Cancer Discov2023
37607920Favorable outcomes of NPM1<sup>mut</sup> AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance.Blood Cancer J2023
36946994Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer.Oncologist2023
37440338A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).Leuk Lymphoma2023
36735393A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma.Blood Adv2023
35078224Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.Blood Adv2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
36085319Impact of TP53 mutations in Triple Negative Breast Cancer.NPJ Precis Oncol2022
33230905Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy.Oncologist2021
33527479CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.Eur J Haematol2021
34706686Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.BMC Cancer2021
34568834Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.Blood Cancer Discov2021
34171263The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.Cancer Cell2021
34168050The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.Clin Cancer Res2021
32513686Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.Proc Natl Acad Sci U S A2020
32094466Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.Leukemia2020
30425048CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.Blood2019
30377918Specific Tumor Characteristics Predict Upstaging in Early-Stage Esophageal Cancer.Ann Surg Oncol2019
29335541Modulation of UVB-induced Carcinogenesis by Activation of Alternative DNA Repair Pathways.Sci Rep2018
30082821Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.Leukemia2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
30381467IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin.J Exp Med2018
29388122Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas.Ann Surg Oncol2018
29743719Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.Leukemia2018
28784769Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.Proc Natl Acad Sci U S A2017
21818064What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants?J Perinatol2012
22825092Delayed umbilical cord clamping in premature neonates.Obstet Gynecol2012
21233796Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity.J Perinatol2011
  • 1 - 29 of 29

Recommended Authors

Mark A Murakami
Dana-Farber Cancer Institute
Career Start Year 2015
Number of shared co-authors 0
Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 0
Zhengming Chen
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 1
Shalin Kothari
Yale University
Career Start Year 2013
Number of shared co-authors 1
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Career Start Year 2012
Number of shared co-authors 17
Taher Abbasi
Cellworks Group Inc.
Career Start Year 2011
Number of shared co-authors 11
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 2
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 6
Yang Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2008
Number of shared co-authors 0
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 12
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 23
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 10
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 0
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 1
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 0
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 4
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 3
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 24
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 6
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Career Start Year 1995
Number of shared co-authors 0
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 7
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 21
Bijal Shah
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 4
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 6
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 26
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 31
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 8

Collaborators

Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 12
Brian J Druker
Oregon Health & Science University
Co-authored papers 11
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 9
Motomi Mori
St Jude Children's Research Hospital.
Co-authored papers 9
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 8
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Nicola Long
Oregon Health and Science University
Co-authored papers 7
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Ronan Swords
Oregon Health and Science University
Co-authored papers 5
Alexey V Danilov
City of Hope National Medical Center
Co-authored papers 5
Bill H Chang
Oregon Health and Science University
Co-authored papers 5
Elie Traer
Oregon Health & Science University
Co-authored papers 4
Angela Rofelty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 3
Isabel English
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Samantha L Savage
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Kevin Watanabe-Smith
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 3
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 3
Tamilla Nechiporuk
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 3
Uma Borate
The Ohio State University
Co-authored papers 3
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 3
Amanda d'Almeida
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
David Tyler Sweeney
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Pierrette Lo
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Ted Laderas
Oregon Health & Science University
Co-authored papers 3
Release 1.2